Status:
COMPLETED
Evaluation of Myocardial Viability by Means of Low-dose Dobutamine Gated SPECT (the DOGS Study)
Lead Sponsor:
University Hospital, Rouen
Collaborating Sponsors:
Bristol-Myers Squibb
GE Healthcare
Conditions:
Coronary Arteriosclerosis
Heart Failure, Congestive
Eligibility:
All Genders
18-80 years
Brief Summary
Viability assessment remains a clinical challenge in patient with coronary artery disease and left ventricular dysfunction. Several imaging modalities are available for evaluating myocardial viability...
Eligibility Criteria
Inclusion
- Documented coronary artery disease
- Left ventricular dysfunction (LVEF \< 50%)
- Patients referred to the Nuclear Medicine department for myocardial viability assessment
- Sinus Rhythm
- Acceptance of a 6-month follow-up
- Signed informed consent
Exclusion
- Recent acute coronary syndrome (\< 21 days)
- Atrial Fibrillation or significant arrhythmias
- Implanted pacemaker
- Contra indication to dobutamine
- Non ischaemic cardiomyopathy
- Pregnancy
Key Trial Info
Start Date :
October 1 2003
Trial Type :
OBSERVATIONAL
End Date :
December 1 2005
Estimated Enrollment :
75 Patients enrolled
Trial Details
Trial ID
NCT00213746
Start Date
October 1 2003
End Date
December 1 2005
Last Update
June 18 2013
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
AZ-VUB
Brussels, Belgium, B 1090
2
Hopital Avicenne
Bobigny, France, 93009
3
CHU de Brest
Brest, France, 29200
4
University Hospital of Caen
Caen, France, 14000